Article

Levofloxacin should be the first choice for antibacterial prophylaxis

Levofloxacin 0.5% eye drops should be the first choice for antibacterial prophylaxis and treatment, according to Professor P. Asbell of the Mount Sinai School of Medicine, USA.

Levofloxacin 0.5% eye drops should be the first choice for antibacterial prophylaxis and treatment, according to Professor P. Asbell of the Mount Sinai School of Medicine, USA.

Professor Asbell, speaking at the Santen lunchtime symposium, reported on a multicentre study aimed at determining the prevalence of resistance among isolates of various bacterial pathogens against antibiotics obtained from patients with eye infections in Germany.

The study was conducted at 35 sites and collected a total of 1,470 ocular isolates between June and November of 2004. Bacteria were identified and EUCAST break points (susceptible - intermediate - resistant) were applied where available. Susceptibility against eight approved antibiotics, with oxacillin as standard, were examined: levofloxacin, ofloxacin, ciprofloxacin, kanamycin, chloramphenicol, erythromycin, colistin and gentamicin.

The results showed that levofloxacin and chloramphenicol provided the best resistance against streptococcus viridans, gentamicin and erythromycin were most resistant to haemophilus influenzae and that levofloxacin and ciprofloxacin were the first choice against pseudomonas aeruginosa.

The results suggest that levofloxacin offers the broadest spectrum of activity against ocular infections. Furthermore, in a separate study in the USA TRUST (Tracking Resistance in the USA Today), the antibiotic maintained this spectrum over a nine year period. The antibiotic is a third generation quinolone that is highly active against ocular pathogens. It is hydrophilic and lipophillic and penetrates well into the anterior chamber.

Professor Asbell concluded that levofloxacin offers the best resistance profile and should be a first choice for antibacterial prophylaxis and treatment.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.